Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules

12 augusti 2026 uppdaterad av: Rigen Biotech

Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules

The purpose of this study is to evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

The prevalence of thyroid nodules by high-resolution ultrasound can be as high as 20%, though most of them are benign lesions, only about 5%-15% are malignant lesions. Based on 1.4 billion population in China, there are approximately 280 million thyroid nodule carriers, of which approximately 14-42 million are potential patients with thyroid cancer. Now thyroid cancer is the fastest growing cancer and the 4th most common cancer in women in China. Therefore, the key point in the evaluation of thyroid nodules is the differential diagnosis of benign and malignant nodules. At present, the commonly used imaging and cytological diagnostic techniques for thyroid nodules include ultrasound and ultrasound-guided fine needle aspiration biopsy (FNAB), as well as emerging molecular diagnostic techniques.

The purpose of this study is to evaluate the accuracy of Thyroscan in the diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features. For patients who have signed an informed consent, the subjects undergo fine needle aspiration of thyroid nodules classified as C-TIRADS catagories 3 or 4 under the guidance of ultrasound or palpation before receiving surgical treatment. One needle is used to prepare cytological smear, and one needle is preserved and sent to Thyroscan detection.

Studietyp

Observationell

Inskrivning (Faktisk)

250

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Hangzhou, Kina, 310000
        • Zhejiang Provincial People's Hospital
      • Shanghai, Kina, 200000
        • Shanghai Jiaotong University School of Medicine
      • Tianjin, Kina, 300000
        • Tianjin Medical University Center Hospital
    • Jiangsu
      • Changzhou, Jiangsu, Kina, 213000
        • The First Peple's Hospital of Changzhou

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients that ultrasound scan identified at least one thyroid nodule, which was classified as category 3 and 4 according to the C-TIRADS guideline.

Beskrivning

Inclusion Criteria:

  1. Patients sign the informed consent form for participating in the reasearch study.
  2. Patient's age is 18 years or older.
  3. Ultrasound showed at least one thyroid nodule, and it was classified as C-TIRADS Category 3/4.
  4. The surgeon has confirmed surgical indication and the subject is willing to undergo the planned surgical intervention at the participating medical institution; or cytology results are benign, and the nodule(s) have remained clinically stable-defined as absence of new high-risk ultrasound features and no significant change in size on serial imaging.
  5. Surgical indications include but are not limited to one of the following conditions: 1) Thyroid nodules are compressed or affect aesthetics; 2) The patient's subjective wishes require surgical removal of the nodules; 3) FNA samples with indeterminate cytology are classified as Bethesda III and IV, requiring diagnostic surgery; 4) After the investigator's assessment, there are other surgical indications.
  6. Preoperative FNAB to obtain sufficient cells.

Exclusion Criteria:

  1. The subject has a history of thyroid tumor.
  2. The subject is not suitable for fine-needle aspiration biopsy and surgical treatment due to other conditions such as comorbid diseases.
  3. Subjects who intend to receive the radiofrequency ablation therapy.
  4. Other conditions determined by the researcher that do not meet the criteria of enrollment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Ultrasound findings of thyroid nodules classified as type 3 and 4 of C-TIRADS
To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To evaluation of Thyroscan's performance in diagnosing thyroid nodules
Tidsram: At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
To explore the sensitivity, specificity, positive predictive value, negative predictive value, consistency and Kappa value of Thyroscan in the diagnosis of thyroid nodules with ultrasound features classified as C-TIRADS category 3/4.
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.

Sekundära resultatmått

Resultatmått
Tidsram
To compared with cytopathology and Thyroscan in diagnosing thyroid nodules.
Tidsram: At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.

Andra resultatmått

Resultatmått
Tidsram
To reveals the correlation between molecular landscape and clinical-pathological characteristics of thyroid nodules.
Tidsram: At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 september 2021

Primärt slutförande (Faktisk)

31 december 2024

Avslutad studie (Faktisk)

31 december 2024

Studieregistreringsdatum

Först inskickad

25 augusti 2021

Först inskickad som uppfyllde QC-kriterierna

25 augusti 2021

Första postat (Faktisk)

27 augusti 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera